Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal stem cell disease characterized by intravascular hemolysis due to the targeting of affected red blood cells by the complement system. Eculizumab and ravulizumab are two monoclonal antibodies that inhibit the complement system’s components and hav...
Main Authors: | Vasantha Mallenahalli Neeekantappa, Ashwin Kamath, Poovizhi Bharathi Rajaduraivelpandian |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1648-9144/60/3/379 |
Similar Items
-
Efficacy and safety of current treatments for paroxysmal nocturnal hemoglobinuria: A systematic review
by: Yara Maria da Silva Pires, et al.
Published: (2023-12-01) -
Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist’s Opinion
by: Guido Gembillo, et al.
Published: (2020-04-01) -
Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ©)
by: Kaiser K, et al.
Published: (2020-04-01) -
Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature
by: Nicole Galli, et al.
Published: (2023-10-01) -
Treatment of paroxysmal nocturnal hemoglobinuria
by: I. A. Lisukov, et al.
Published: (2014-07-01)